Tatevik Hovakimyan: Proud to Be Part of This Important Health Economic Project
Tatevik Hovakimyan, Co-Founder and CEO at CardioLab Medical Center, reposted Philippe Timmermans’s post on LinkedIn:
“Proud to be part of this important health economic project.”
Quoting Philippe Timmermans’s post:
“If you would build your health care system from the ground up, where would you start? Which interventions would you prioritize? Or, if health care expenditure is limited, which interventions would you prefer above others?
The ESC guidelines provide us invaluable insights for clinical practice, but lack a health economical perspective. Formal health technological assessments can provide insights in cost-effectiveness of a certain intervention, but is not available for every treatment modality, is country/health care system specific and comes with an intrinsic financial cost.
Therefore, we developed a novel framework that acts as a ‘go between’, assessing both clinical impact, complexity of implementation and quantification of clinical endpoints at a fixed time interval – irrespective of health care system. Dedicated visualization of the paramaters was developed, based on the current layout of the ESC guidelines but integrating both the novel qualitative and quantitative parameters. The 2021/2023 ESC heart failure guidelines were used to deploy this novel framework. The paper of this pilot project, supported by the ESC, is published in the European Heart Journal Quality of Care and Clinical Outcomes – check it out here.
Title: Priority measures for implementation: an ESC pilot linking guidelines to practice
Authors: Philippe Timmermans, Jr, Clara E E van Ofwegen, Filip Zemrak, Janneke W C M Mulder, Fenny Shidhika, Tatevik Hovakimyan, Theresa A McDonagh, Marco Metra, Eva Prescott, Eric Boersma
It is aimed at facilitating interaction between health care professionals and health policy stakeholders. As this framework is the product of many brainstorm sessions, statistical analysis, writing and rewriting, the authors are eager to hear feedback from our peers in both the clinical, health economical and health policy field. Please do share your thoughts, comments, criticism and suggestions to further improve this new framework, which we believe can be the first step in a further integration between clinical research and health economics.
I would like to thank all co-authors for the collaboration, inspiration and opportunities to work on this seminal paper.”
Explore more posts for deeper insights into hemostasis with Hemostasis Today.
-
Feb 20, 2026, 17:35Wolfgang Miesbach: Plasma FIX Is Only Part of the Story In Haemophilia B
-
Feb 20, 2026, 17:27Sheharyar Raza: Examining Guideline Discordance in Evidence-Based Apheresis Recommendations
-
Feb 20, 2026, 17:23Barbara Mora: Newly Discovered EPO Gene Intronic Variant as a Cause of Congenital Erythrocytosis
-
Feb 20, 2026, 16:48Miguel Brito: Newborn Screening and Challenges in Follow-Up Care for Sickle Cell Disease in Angola
-
Feb 20, 2026, 16:41Uche Kennedy: Hemophilia Care Needs Systems Reform, Not Short-Term Fixes
-
Feb 20, 2026, 16:33Sonal Sonu: Real Clinical Maturity is Knowing When to Stop
-
Feb 20, 2026, 16:27Clear Recommendations for Daily Management and Family Support in Hemophilia A – WFH
-
Feb 20, 2026, 15:56Alan Nurden: Highlighting the Role of Activated Platelets in Heart and Kidney Complications of Diabetes
-
Feb 20, 2026, 15:51Domenico Girelli: Continuing Commitment to Rare Disease Research